Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if autologous nonmyeloablative hematopoietic stem cell transplantation is able to induce prolonged and significant increases of C-peptide levels associated with absence of or reduction of daily insulin.

Clinical Trial Description

Patients with type 1 DM depend on exogenous insulin administration for survival and for control of long-term complications. The best-established treatment is tight control of blood glucose achieved by frequent daily injections or continuous subcutaneous infusion of insulin, ie, intensive insulin therapy. Although insulin therapy has developed enormously, even the most modern technologies do not allow the maintenance of normoglycemia.

Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees.

Controlled trials and further biological studies are necessary to confirm the role of this treatment in changing the natural history of type 1 DM.

This is a prospective pilot study which will enroll patients with type 1 diabetes mellitus within the first months of diagnosis, with clinical and laboratory findings. The donor stimulation will be with cyclophosphamide, filgrastim, and mesna. The cells will be recollected from peripheral blood by apheresis and refrigerated. The patients will receive a nonmyeloablative conditioning regimen with cyclophosphamide and fludarabine, and after this, the cells will be injected intravenously. They will receive a standard regimen of post-transplant prophylaxis. The duration of use of this prophylactic drugs scheme depends on the patient's recovery time. The reinfusion of stem cells will be completed after the last dose of cyclophosphamide, through a peripheral vein.

Lately, every three months, the C-Peptide levels, glucose and insulin serum levels will be measured. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01121029
Study type	Interventional
Source	Hospital Universitario Dr. Jose E. Gonzalez
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	May 2010
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04476472` - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort	N/A
Completed	`NCT03635437` - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes	Phase 1/Phase 2
Completed	`NCT04909580` - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes	N/A
Active, not recruiting	`NCT00679042` - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol	Phase 3
Completed	`NCT03293082` - Preschool CGM Use and Glucose Variability in Type 1 Diabetes	N/A
Completed	`NCT04016662` - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)	Phase 4
Completed	`NCT02527265` - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients	Phase 2
Completed	`NCT03738865` - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes	Phase 3
Completed	`NCT03240432` - Wireless Innovation for Seniors With Diabetes Mellitus	N/A
Completed	`NCT03168867` - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)	N/A
Completed	`NCT03674281` - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System	N/A
Completed	`NCT03669770` - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting	`NCT03682640` - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes	Phase 2
Recruiting	`NCT04096794` - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed	`NCT02882737` - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus	N/A
Recruiting	`NCT02745808` - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Withdrawn	`NCT02579148` - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Completed	`NCT02558491` - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM	N/A
Completed	`NCT02562313` - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®	Phase 1
Withdrawn	`NCT02518022` - How to be Safe With Alcoholic Drinks in Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.